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We report the case of a 42-year-old woman receiving
voriconazole for a fungal endophthalmitis, who presented with
diffuse and severe musculoskeletal pain after 4 months of
therapy. In the absence of an obvious aetiology, the patient was
referred for three-phase bone scintigraphy. The anterior whole-
body scan acquired 20 min after injection showed multiple and
intense linear-shaped foci throughout the skeleton affecting
predominantly the diaphyses of the long bones (a),
corresponding to increased tracer uptake in the cortical bone
on the delayed anterior whole-body scan affecting the upper
and lower limbs, clavicles, scapulas and ribs (b, c).
In a recent case series of transplant recipients receiving
long-term voriconazole therapy, a painful periostitis was
associated with fluoride excess [1]. Wang et al. [2] reported
a series of five patients with possibly drug-induced periostitis
associated with voriconazole administration. These patients
presented clinically with “secondary hypertrophic osteo-
arthropathy”, a syndrome usually characterized by digital
clubbing, diffuse periostosis of the tubular bones and
synovial effusions [3]. In our patient, a nodular periostitis
and only a slight focal lamellar periosteal reaction around the
radial and pretibial diaphyses were observed on review of the
scintigraphy-guided conventional radiograph.
As this severe adverse event was probably associated
with voriconazole, therapy was promptly stopped. Five
days after discontinuation, all clinical symptoms had
resolved and the radiographic anomalies had decreased at
the 4-month follow-up.
This case report illustrates the key role of three-phase
bone scintigraphy for the investigation of patients with
atypical skeletal symptoms.
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